Compare ASC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | ANNX |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.7M | 873.3M |
| IPO Year | 2013 | 2020 |
| Metric | ASC | ANNX |
|---|---|---|
| Price | $19.02 | $4.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $17.00 | $16.50 |
| AVG Volume (30 Days) | 577.6K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16,320.74 |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.31 | $2.54 |
| 52 Week High | $20.03 | $7.18 |
| Indicator | ASC | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 38.99 |
| Support Level | $18.14 | N/A |
| Resistance Level | $18.91 | $5.63 |
| Average True Range (ATR) | 0.53 | 0.21 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 79.07 | 37.74 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.